Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Long-term clinical efficacy of grass-pollen immunotherapy

Article Abstract:

Grass-pollen immunotherapy for three or four years can prevent hay-fever in many patients. Researchers evaluated the incidence of hay-fever in 16 patients who had received grass-pollen immunotherapy for three or four years but then stopped the treatment. The rate of hay-fever symptoms and antihistamine use did not differ in these patients from 16 patients who continued to receive immunotherapy. Hay-fever symptoms and antihistamine use were also much lower than in a similar group of patients who never received immunotherapy.

Author: Durham, Stephen R., Walker, Samantha M., Varga, Eva-Maria, Jacobson, Mikila R., O'Brien, Fiona, Noble, Wendy, Till, Stephen J., Hamid, Qutayba A., Nouri-Aria, Kayhan T.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1999
Hay-fever, Hay fever

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma

Article Abstract:

Interferon gamma-1b does not appear to improve the prognosis of patients with a type of kidney cancer called renal-cell carcinoma. Researchers gave 181 patients with renal-cell carcinoma weekly injections of interferon gamma-1b or a placebo. All the patients had metastatic cancer and the primary tumor had been treated. Only 4.4% of those receiving interferon gamma-1b responded, compared to a 6.6% response rate in those receiving a placebo. Interferon gamma-1b did not reduce disease progression or improve survival rates.

Author: Moore, Malcolm J., Bajamonde, Alex, Fradet, Yves, Davis, Ian, Gleave, Martin E., Elhilali, Mostafa, Venner, Peter, Saad, Fred, Klotz, Laurence H., Paton, Virginia
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1998
Interferon gamma

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Cancer immunotherapy with alloreactive lymphocytes

Article Abstract:

Immunotherapy using allogeneic lymphocytes requires ensuring the prevention of donor's T cell rejection and avoidance of toxicity and mortality inherent in the procedure. Infusions of allogeneic stem-cells without the abalation of the bone marrow cells has been found to be an effective treatment in patients with metastatic renal-cell cancer. The therapeutic importance of the procedure lies in the fact that the regression of metastases is delayed for months subsequent to the onset of graft-versus-host disease.

Author: Slavin, Shimon
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2000
Israel, Editorial, Physiological aspects, Stem cells, Stem cell transplantation, Lymphocytes, Graft versus host reaction, Graft vs. host disease

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Care and treatment, Evaluation, Immunotherapy, Carcinoma, Renal cell, Renal cell carcinoma
Similar abstracts:
  • Abstracts: Cell encapsulation: promise and progress. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine
  • Abstracts: Longitudinal weight changes over four years and other associated health factors in 629 men and women aged over 65
  • Abstracts: Placental production of estradiol and progesterone after oocyte donation in patients with primary ovarian failure
  • Abstracts: The antiestrogenic effect of cigarette smoking in women. Secretory component of immunoglobulin A in maternal serum and the prediction of preterm delivery
  • Abstracts: Partial normalization by dietary cod-liver oil of increased microvascular albumin leakage in patients with insulin-dependent diabetes and albuminuria
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.